Get the Stockscreener App
2.26
0.89%
0.02
In 8 Bio Inc stock is traded at $2.26, with a volume of 44,685.
It is up +0.89% in the last 24 hours and down -4.64% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.24
Open:
$2.24
24h Volume:
44,685
Relative Volume:
0.23
Market Cap:
$10.26M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-3.0133
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-4.64%
1M Performance:
-4.64%
6M Performance:
-72.25%
1Y Performance:
-85.52%
1-Day Range:
$2.227
$2.34
1-Week Range:
$2.1004
$2.44
52-Week Range:
$1.98
$17.64
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.26 | 10.85M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Mustang Bio Inc. stock trend forecastJuly 2025 Summary & Verified Momentum Watchlists - Newser
Volume spikes in Palisade Bio Inc. stock – what they meanWeekly Market Outlook & Precise Swing Trade Alerts - Newser
Using economic indicators to assess Cabaletta Bio Inc. potentialWeekly Market Outlook & Low Volatility Stock Suggestions - Newser
Is Third Harmonic Bio Inc. building a consolidation baseJuly 2025 Catalysts & Long-Term Capital Growth Strategies - Newser
Heatmap analysis for Gossamer Bio Inc. and competitorsMarket Movers & Fast Exit Strategy with Risk Control - Newser
Combining price and volume data for Kronos Bio Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
Regression analysis insights on Gossamer Bio Inc. performanceBreakout Watch & High Return Trade Guides - Newser
Sentiment Tools Show Shift in Trader Mood on Cabaletta Bio Inc.2025 Sector Review & Community Driven Trade Alerts - beatles.ru
Gossamer Bio Inc.’s Beta Climbs After Market VolatilityJuly 2025 Summary & High Yield Stock Recommendations - classian.co.kr
GRI Bio CEO to Showcase NKT Cell Therapy Pipeline at Webull Biotech Investor Event - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Is Tourmaline Bio Inc. stock ready for a breakoutFree Alpha Driven Watchlist With Alerts - Newser
Belite Bio Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Korro Bio Inc expected to post a loss of $2.56 a shareEarnings Preview - TradingView
Annovis Bio Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
MUSTANG BIO, INC. SEC 10-Q Report - TradingView
REPEATTevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions - uk.finance.yahoo.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Instil Bio Inc expected to post a loss of $2.50 a shareEarnings Preview - TradingView
KALA BIO, Inc. SEC 10-Q Report - TradingView
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts - The Globe and Mail
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioVie Inc. Announces Pricing of $12 Million Public Offering - The Manila Times
Gossamer Bio Expands Team with 168,750 Share Options Grant at $2.16 Exercise Price - Stock Titan
INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes - Stock Titan
Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth - Stock Titan
Nuvation Bio Reports 1,043% YoY Sales Growth, Exceeds Revenue Estimates with $4.8 Million in GAAP Revenue - AInvest
Palisade Bio Reports 100% Clinical Response in Phase 1b - GlobeNewswire
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
New Lung Cancer Drug IBTROZI Gains FDA Approval, Reaches 70 Patients in First 7 Weeks - Stock Titan
How sentiment analysis helps forecast Instil Bio Inc.Insider Strategy for High Conviction Picks - Newser
Can technical indicators confirm Belite Bio Inc Depositary Receipt’s reversalFree Weekly Return Pick Forecast Reports - Newser
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc. - Bluefield Daily Telegraph
7 Dividend Stocks for 2025 — Some Pay Over 8%, Some Just Refuse to Die - The Globe and Mail
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
Q32 Bio Secures FDA Fast Track for Alopecia Treatment as Phase 2 Trial Advances with $54.8M Runway - Stock Titan
Climb Bio Inc. stock daily chart insightsFree ROI Driven Equity Selection With Safety - Newser
Adicet Bio's Gamma Delta T Cell Therapy Updates Coming at Major Growth Conference - Stock Titan
INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan
What drives Upstream Bio Inc. stock priceDynamic profit expansion - Jammu Links News
Should I hold or sell Third Harmonic Bio Inc. stock in 2025Unlock expert market analysis instantly - Jammu Links News
Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - jammulinksnews.com
How many analysts rate bluebird bio Inc. as a “Buy”Low Risk Alerts Backed By Experts - Jammu Links News
10 Penny Stocks That Will Skyrocket - Insider Monkey
What makes INmune Bio Inc. stock price move sharplyBreakout Stocks Tracker With High Returns - Jammu Links News
Nasdaq Compliance Regained: Passage Bio Stock Price Meets Minimum Requirement - AInvest
INmune Bio to Present Q2 2025 Financial Results and Key Clinical-Stage Updates on August 7 - Stock Titan
What are the latest earnings results for Climb Bio Inc.Advanced Screener Growth Plan For Fast Growth - Jammu Links News
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
In 8 Bio Inc Stock (INAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCall Patrick | CHIEF FINANCIAL OFFICER |
Apr 30 '25 |
Option Exercise |
0.18 |
15,000 |
2,766 |
67,071 |
| Roemer Alan S. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
113,459 |
20,922 |
398,489 |
| Brandt Peter C. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
163,934 |
30,229 |
681,538 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):